Diese Übersetzung wird noch vorbereitet. Bis dahin zeigen wir vorübergehend die englische Originalversion.
Geschäft · 10.2.20141 Min. Lesezeit
Serious Drug-Induced Liver Injury: Who Gets It? Who Doesn't? Why?; Public Conference; Request for Comments
Lokale automatische Übersetzung · Originalsprache der Quelle
Zusammenfassung
The Food and Drug Administration (FDA) is announcing a public conference entitled "Serious Drug-Induced Liver Injury (DILI): Who Gets It? Who Doesn't? Why?" This conference will be cosponsored with the Critical Path Institute (C-Path) and the Pharmaceutical Research and Manufacturers of America. Its purpose is to discuss, debate, and share views among stakeholders in the pharmaceutical industry, academia, health care providers, patient groups, and regulatory bodies on how best to detect and assess the severity, extent, and likelihood of drug causation of liver injury and dysfunction in people using drugs for any medical purpose.
Originalsprache der Quelle: Federal Register — Food and Drug AdministrationOriginalquelle öffnen →